SBIO vs. GSKH

Last updated Jun 21, 2026

SBIO (ALPS Medical Breakthroughs ETF) and GSKH (GSK plc ADRhedged ETF) are both Health & Biotech Equities funds - SBIO tracks the S-Network Medical Breakthroughs Index while GSKH tracks the GSK plc Local Shares Total Return. Both are passively managed. Over the past year, SBIO returned 83.70% vs 39.42% for GSKH. At a 0.30 correlation, their price movements are largely independent. SBIO charges 0.50%/yr vs 0.19%/yr for GSKH.

Performance

SBIO vs. GSKH - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in ALPS Medical Breakthroughs ETF (SBIO) and GSK plc ADRhedged ETF (GSKH). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

The year-to-date returns for both stocks are quite close, with SBIO having a 7.59% return and GSKH slightly lower at 7.33%.

SBIO

• 1D: 1.59%
• 1M: 2.43%
• YTD: 7.59%
• 6M: 7.72%
• 1Y: 83.70%
• 3Y*: 20.44%
• 5Y*: 3.03%
• 10Y*: 9.87%

GSKH

• 1D: -1.73%
• 1M: 0.17%
• YTD: 7.33%
• 6M: 7.39%
• 1Y: 39.42%
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

SBIO vs. GSKH - Yearly Performance Comparison

	2026 (YTD)	2025
SBIO ALPS Medical Breakthroughs ETF	7.59%	53.56%
GSKH GSK plc ADRhedged ETF	7.33%	36.51%

Correlation

The correlation between SBIO and GSKH is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (All Time) Calculated using the full available price history since Jan 7, 2025	0.30

Return for Risk

SBIO vs. GSKH — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SBIO

SBIO Risk / Return Rank: 87
SBIO Sharpe Ratio Rank: 89
SBIO Sortino Ratio Rank: 86
SBIO Omega Ratio Rank: 77
SBIO Calmar Ratio Rank: 94
SBIO Martin Ratio Rank: 88

GSKH

GSKH Risk / Return Rank: 41
GSKH Sharpe Ratio Rank: 41
GSKH Sortino Ratio Rank: 44
GSKH Omega Ratio Rank: 42
GSKH Calmar Ratio Rank: 41
GSKH Martin Ratio Rank: 36

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SBIO vs. GSKH - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for ALPS Medical Breakthroughs ETF (SBIO) and GSK plc ADRhedged ETF (GSKH). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	SBIO	GSKH	Difference
Sharpe ratio: Return per unit of total volatility	2.78	1.41	+1.37
Sortino ratio: Return per unit of downside risk	3.63	2.14	+1.49
Omega ratio: Gain probability vs. loss probability	1.43	1.27	+0.16
Calmar ratio: Return relative to maximum drawdown	6.55	1.99	+4.56
Martin ratio: Return relative to average drawdown	18.25	5.27	+12.98

SBIO vs. GSKH - Sharpe Ratio Comparison

The current SBIO Sharpe Ratio is 2.78, which is higher than the GSKH Sharpe Ratio of 1.41. The chart below compares the historical Sharpe Ratios of SBIO and GSKH, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

SBIO vs. GSKH - Drawdown Comparison

The maximum SBIO drawdown since its inception was -63.06%, which is greater than GSKH's maximum drawdown of -18.54%. Use the drawdown chart below to compare losses from any high point for SBIO and GSKH.

Drawdown Indicators

	SBIO	GSKH	Difference
Max Drawdown Largest peak-to-trough decline	-63.06%	-18.54%	-44.52%
Max Drawdown (1Y) Largest decline over 1 year	-12.66%	-18.54%	+5.88%
Max Drawdown (3Y) Largest decline over 3 years	-42.44%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-53.10%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-63.06%	—	—
Current Drawdown Current decline from peak	-10.12%	-13.70%	+3.58%
Average Drawdown Average peak-to-trough decline	-28.38%	-5.82%	-22.56%
Ulcer Index Depth and duration of drawdowns from previous peaks	4.53%	6.98%	-2.45%

Volatility

SBIO vs. GSKH - Volatility Comparison

ALPS Medical Breakthroughs ETF (SBIO) has a higher volatility of 9.99% compared to GSK plc ADRhedged ETF (GSKH) at 6.48%. This indicates that SBIO's price experiences larger fluctuations and is considered to be riskier than GSKH based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	SBIO	GSKH	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.99%	6.48%	+3.51%
Volatility (6M) Calculated over the trailing 6-month period	23.01%	18.48%	+4.53%
Volatility (1Y) Calculated over the trailing 1-year period	29.78%	26.20%	+3.58%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	33.62%	26.92%	+6.70%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	33.17%	26.92%	+6.25%

SBIO vs. GSKH - Expense Ratio Comparison

SBIO has a 0.50% expense ratio, which is higher than GSKH's 0.19% expense ratio.

Dividends

SBIO vs. GSKH - Dividend Comparison

SBIO has not paid dividends to shareholders, while GSKH's dividend yield for the trailing twelve months is around 2.89%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017
GSKH GSK plc ADRhedged ETF	2.89%	1.15%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SBIO ALPS Medical Breakthroughs ETF	0.00%	0.00%	3.55%	0.22%	0.00%	0.00%	0.00%	0.04%	2.79%	1.77%

Frequently Asked Questions

Can I hold both SBIO and GSKH in my portfolio?

SBIO and GSKH have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, SBIO or GSKH?

SBIO has higher volatility (9.99%) compared to GSKH (6.48%). In terms of maximum drawdown, SBIO dropped -63.06% vs GSKH's -18.54%.

Which ETF is better, SBIO or GSKH?

On 1-year performance, SBIO leads with 83.70% vs 39.42% for GSKH. On fees, GSKH is cheaper at 0.19% per year. On volatility, GSKH has been the lower-risk option at 6.48%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, SBIO or GSKH?

Over the 1-year period, SBIO has performed better with a 83.70% return vs 39.42%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, SBIO or GSKH?

GSKH is cheaper with a 0.19% expense ratio, compared with 0.50% for SBIO.

Which ETF pays a higher dividend yield, SBIO or GSKH?

GSKH has the higher dividend yield at 2.89%, compared with 0.00% for SBIO.

What is the main difference between SBIO and GSKH?

SBIO tracks S-Network Medical Breakthroughs Index, while GSKH tracks GSK plc Local Shares Total Return. They also come from different issuers: SS&C and ADRhedged. Their fees differ too: 0.50% for SBIO and 0.19% for GSKH.

Which has better risk-adjusted returns?

SBIO currently has the higher Sharpe Ratio (2.78 vs 1.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.